God effekt av vareniklin vid snusavvänjning. Läkemedlet jämfört med placebo i dubbelblindad studie
Engelsk titel: Good effect of varenicline in snuff use cessation. Double-blind placebo controlled comparative study
Läs online
Författare:
Fagerström, Karl Olov
;
Gilljam, Hans
;
Tonstad, Serena
Email: karl.fagerstrom@swipnet.se
Språk: Swe
Antal referenser: 11
Dokumenttyp:
RCT
UI-nummer: 11111200
Sammanfattning
The purpose was to assess the efficacy and safety of the ?4?2 nicotinic acetylcholine receptor partial agonist, varenicline, in helping users of smokeless tobacco to quit. Subjects consisted of 431 smokeless tobacco users (> 8 ST administrations/day) treated with varenicline 1 mg twice daily or placebo for 12 weeks, with 14 weeks post-treatment follow-up. Week 9-12 continuous abstinence rate was significantly higher for varenicline than placebo (59% v 39.0%: relative risk 1.60: p<0.001. The advantage of varenicline over placebo persisted through the 14 weeks of follow-up (continuous abstinence rates of 45% v 34%; relative risk 1.42: p<0.012). The most frequent adverse events in the varenicline versus placebo groups were nausea (34.7% v 6.4%), fatigue (10.3% v 6.9%), headache (10.3% v 9.2%), and sleep disorder (10.3% v 6.9%). Varenicline, that has demonstrated significant efficacy as a smoking cessation aid, also seems to be efficacious for cessation from another form of nicotine/tobacco use, i.e. smokeless tobacco.